SCHEMBL25962494

SCHEMBL25962494

C=C(CCNC(=O)COc1ccc(Cl)cc1)NC

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.53
▸ CYP1A2 P05177 1/20 0.53
▸ CYP2C9 P11712 1/20 0.53
▸ CYP2C19 P33261 1/20 0.53
▸ HTT P42858 1/20 0.53
▸ HDAC1 Q13547 1/20 0.52
▸ SMN1; SMN2 Q16637 1/20 0.52
▸ MEN1 O00255 5/20 0.50
▸ KMT2A Q03164 5/20 0.50
▸ TDP1 Q9NUW8 1/20 0.50
▸ ALDH1A1 P00352 1/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ RAB9A P51151 1/20 0.49
▸ NPY1R P25929 1/20 0.48
▸ PKM P14618 1/20 0.48
▸ BCHE P06276 1/20 0.48
▸ ACHE P22303 1/20 0.48
▸ GAA P10253 1/20 0.48
▸ ALOX12 P18054 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23383747 0.90 CYP1A2 (0.49) KDM4ECYP1A2CYP2C9CYP2C19HTT
SCHEMBL23182908 0.88 KDM4E (0.54) KDM4ECYP1A2CYP2C9CYP2C19HTT
SCHEMBL23383744 0.87 HTT (0.57) KDM4ECYP1A2CYP2C9CYP2C19HTT
SCHEMBL23383660 0.86 KDM4E (0.51) KDM4ECYP1A2CYP2C9CYP2C19HTT
SCHEMBL23383779 0.86 MEN1 (0.50) KDM4ECYP1A2CYP2C9CYP2C19HTT
SCHEMBL23182604 0.85 KMT2A (0.54) KDM4ECYP1A2CYP2C9CYP2C19HTT
SCHEMBL23384172 0.85 MEN1 (0.49) KDM4ECYP1A2CYP2C9CYP2C19HTT
SCHEMBL23384162 0.85 KMT2A (0.49) KDM4ECYP1A2CYP2C9CYP2C19HTT
SCHEMBL23182881 0.85 HDAC1 (0.61) KDM4EHTTHDAC1SMN1; SMN2MEN1
SCHEMBL23182495 0.84 TDP1 (0.54) KDM4ECYP1A2CYP2C9CYP2C19HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250072-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 DENALI THERAPEUTICS INC. 2023-08-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250072-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 EIF2A, EIF4A2, EIF4EBP1 KDM4E 2956/4885CYP1A2 4419/4885CYP2C9 4857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback